MétaCan
Menu
Back to cohort
Record W4205962195 · doi:10.1186/s13063-021-05848-8

Clinical efficacy of iodine complex in SARS-CoV-2-infected patients with mild to moderate symptoms: study protocol for a randomized controlled trial

2022· article· en· W4205962195 on OpenAlexaff
Sohaib Ashraf, Shoaib Ashraf, Moneeb Ashraf, Iqra Farooq, Rutaba Akmal, Muhammad Imran, Larab Kalsoom, Sidra Ashraf, Sundas Rafique, Muhammad Ghufran, Muhammad Kiwan Akram, Sohaib-ur-Rehman, Muhammad Faisal Nadeem, Nazish Matti, Uzma Nasim Siddiqui, Ayesha Humayun, Qazi Abdul Saboor, Ali Ahmad, Muhammad Ashraf, Mateen Izhar, Zaigham Habib, Kanwal Hayat, Ghazala Amjad, Misbah Kousar, Shahroze Arshad, Umair Hafeez, Tayyab Mughal, Muhammad Sikandar Saleem, Ammara Ahmad, Abeer Bin Awais, Noman Khalid, Qurat-ul-Ain Iqbal, Muhammad Hassan, Abdul Rehman Virk, Mehak Gul, Muhammad Naeem, Roa Umer, Musa Khalil, Tayyaba Muzafar, Sibgha Zulfiqar, Saadia Shahzad Alam, Emed Chohan, Muhammad Imran Anwar, Ali Rafique Mirza, Amber Malik, Talha Mahmud, Adeen Akmal, Syed Sami Husain Sherazi, Zartasha Safdar, Sohail Ahmad, Ali Arshad, Khawar Nawaz, Muhammad Ismail Khalid Yousaf

Bibliographic record

VenueTrials · 2022
Typearticle
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsUniversité de MontréalCentre Hospitalier Universitaire Sainte-Justine
Fundersnot available
KeywordsMedicineRandomized controlled trialProtocol (science)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialSars virusCoronavirus disease 2019 (COVID-19)Physical therapyAlternative medicineInternal medicinePathologyDisease

Abstract

fetched live from OpenAlex

BACKGROUND: Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus-infected millions globally. Despite a wide range of advised options for the treatment of COVID-19, a single strategy to tackle this pandemic remains elusive, thus far. That is why we are conducting a clinical trial to find out the efficacy of iodine complex to clear a viral load of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) along with a reduction in time taken to alleviate symptoms. METHOD: The proposed study is a placebo-controlled, add-on, randomized trial using parallel group designs. This is a closed-label and adaptive with sample size reassessment, multi-centered design with a 1:1:1:1 allocation ratio and superiority framework. It will be conducted in Shaikh Zayed Post-Graduate Medical Complex, Ali Clinic, and Doctors Lounge, Lahore, Pakistan. This study will have three arms of mild to moderately symptomatic COVID-19 patients (50 patients in each) which will receive ionic-iodine polymer complex with 200 mg of elemental iodine: interventional arm A will have encapsulated, arm B will receive suspension syrup form, arm C will get throat spray, while arm X will be standard care with placebo. Data will be collected on self-constructed, close-ended questionnaires after obtaining written consent. Data will be analyzed using SAS version 9.4. COVID-19 patients will be monitored by RT-PCR and HRCT (high-resolution computed tomography) chest. In addition to these, the duration of the symptomatic phase and mortality benefits will be analyzed in both groups. DISCUSSION: The study is designed to measure the superior efficacy of the iodine complex as an add-on in treating COVID-19-positive patients with mild to moderate symptoms. This combination is hypothesized to improve various parameters like rapid viral load reduction, clinical and radiological improvement, lower mortality, and reduction in hospitalization. The trial will aid in devising a better strategy to cope with COVID-19 in a relatively inexpensive and accessible way. The implications are global, and this could prove itself to be the most manageable intervention against COVID-19 especially for patients from limited-resource countries with deprived socioeconomic status. TRIAL REGISTRATION: ClinicalTrials.gov NCT04473261 . Registered on July 16, 2020.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.035
metaresearch head score (Gemma)0.328
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.293
Threshold uncertainty score0.994

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0350.328
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0090.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.305
GPT teacher head0.576
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueTrialsSame topicCOVID-19 Clinical Research StudiesFrench-language works237,207